Jon Wilner's Pac-12 Hotline mailbag: A look at if New Mexico is a possibility for Pac-12 expansion, and whether USC and UCLA's non-revenue programs might return to the conference.

In draft guidance, NICE has said it cannot recommend Gilead Sciences' Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the drug via the NHS in the UK. The ...